134058-08-5

Basic information

• Product Name: 3-(3-methoxy-4-methylphenyl)-2-propenoic acid ethyl ester
• Synonyms: 3-(3-methoxy-4-methylphenyl)-2-propenoic acid ethyl ester
• CAS NO: 134058-08-5
• Molecular Weight: 220.268
• Mol File: 134058-08-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-(3-methoxy-4-methylphenyl)-2-propenoic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3-methoxy-4-methylphenyl)-2-propenoic acid ethyl ester(134058-08-5)
• EPA Substance Registry System: 3-(3-methoxy-4-methylphenyl)-2-propenoic acid ethyl ester(134058-08-5)

Safety Data

• Hazardous Substances Data: 134058-08-5(Hazardous Substances Data)

Upstream product

• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 24973-22-6 3-methoxy-4-methylbenzaldehyde 
• 578-58-5 2-methylmethoxybenzene 
• 140-88-5 ethyl acrylate 

Downstream Products

• 132980-20-2 3-(3-Methoxy-4-methylphenyl)-2-propenoic acid 
• 134057-99-1 (E)-3-(3-methoxy-4-methylphenyl)acrylaldehyde 

Relevant articles and documents

S,O-Ligand-Promoted Pd-Catalyzed C?H Olefination of Anisole Derivatives

The C?H olefination of substituted anisole derivatives by a Pd/S,O-ligand catalyst is reported. The reaction proceeds under mild conditions with a broad range of substituted aryl ethers bearing both electron donating and withdrawing substituents at ortho,

Benzylideneacetone Derivatives Inhibit Osteoclastogenesis and Activate Osteoblastogenesis Independently Based on Specific Structure-Activity Relationship

(E)-3,4-Dihydroxybenzylideneacetone (compound 1) inhibited receptor activator of NF-κB ligand-induced osteoclastogenesis of C57BL/6 bone marrow monocyte/macrophages with IC50 of 7.8 μM (IC50 of alendronate, 3.7 μM) while stimulating the differentiation of MC3T3-E1 osteoblastic cells, accompanied by the induction of Runt-related transcription factor 2, alkaline phosphatase, and osteocalcin. (E)-4-(3-Hydroxy-4-methoxyphenyl)-3-buten-2-one (compound 2c) showed a dramatically increased osteoclast-inhibitory potency with IC50 of 0.11 μM while sustaining osteoblast-stimulatory activity. (E)-4-(4-Hydroxy-3-methoxyphenyl)-3-buten-2-one (compound 2g) stimulated alkaline phosphatase production 2-fold at 50 μM without changing osteoclast-inhibitory activity, compared with compound 1. Oral administration of compounds 1, 2c, and 2g prevented ovariectomy-induced osteoporosis in ddY mice to a degree proportional to their osteoclastogenesis-inhibitory potencies. The administration of 1 (mg/kg)/d compound 2c ameliorated histomorphometry of osteoporotic bone to a degree comparable with 10 (mg/kg)/d alendronate. Conclusively, the in vitro capacity of a few benzylideneacetone derivatives to inhibit osteoclastogenesis supported by independent osteoblastogenesis activation was convincingly reflected in in vivo management of osteoporosis, suggesting a potential novel therapeutics for osteopenic diseases.